EOSINOPHILIC GRANULOMATOSIS WITH POLYANGIITIS
Clinical trials for EOSINOPHILIC GRANULOMATOSIS WITH POLYANGIITIS explained in plain language.
Never miss a new study
Get alerted when new EOSINOPHILIC GRANULOMATOSIS WITH POLYANGIITIS trials appear
Sign up with your email to follow new studies for EOSINOPHILIC GRANULOMATOSIS WITH POLYANGIITIS, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New hope for rare disease: drug may tame inflammation and cut steroid use
Disease control OngoingThis study tests whether a drug called mepolizumab can help people with a rare disease called EGPA (which causes inflammation in blood vessels, lungs, and sinuses) reach remission better than standard treatments. About 100 adults with active EGPA will receive either mepolizumab o…
Matched conditions: EOSINOPHILIC GRANULOMATOSIS WITH POLYANGIITIS
Phase: PHASE3 • Sponsor: Assistance Publique - Hôpitaux de Paris • Aim: Disease control
Last updated May 18, 2026 12:11 UTC
-
New hope for rare disease: depemokimab aims to tame EGPA with fewer steroids
Disease control OngoingThis study compares a new drug, depemokimab, to an existing one, mepolizumab, in adults with a rare inflammatory disease called EGPA. The goal is to see if depemokimab can help patients achieve and maintain remission (no symptoms and low steroid use) over 52 weeks. Participants m…
Matched conditions: EOSINOPHILIC GRANULOMATOSIS WITH POLYANGIITIS
Phase: PHASE3 • Sponsor: GlaxoSmithKline • Aim: Disease control
Last updated Apr 30, 2026 15:50 UTC